Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials

Abstract

This study was to evaluate the efficacy and safety of early application of citicoline in the treatment of patients with acute stroke by meta-analysis. Randomized controlled trials published until May 2015 were electronically searched in MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, WHO International Clinical Trial Registration Platform, Clinical Trial.gov, and China Biology Medicine disc. Two reviewers independently screened the articles and extracted the data based on the inclusion and exclusion criteria. The quality of included articles was evaluated by using Revman5.0, and meta-analysis was performed. The results showed that 1027 articles were obtained in initial retrieval, and finally 7 articles, involving a total of 4039 cases, were included for analysis. The meta-analysis showed that no significant differences were found in the long-term mortality (OR=0.91, 95% CI 0.07 to 1.09, P=0.30), the rate of dependency (OR=1.02, 95% CI 0.87 to 1.24, P=0.85), and the effective rate (OR=0.98, 95% CI 0.84 to 1.14, P=0.82) between citicoline group and control group. The overall rate of adverse events in citicoline group was not significantly different from that in control group (P=0.30). The quality of included articles reached moderate-low level. In conclusion, citicolne cannot reduce long-term mortality and dependence rate in the treatment of acute stroke, and the effective rate of citivoline may be not better than that of controls but with reliable safety.

Keywords

cytidine diphosphate choline / acute stroke / meta-analysis / randomized controlled trials

References

[1] World Health Organization. World Health statistics 2008. Geneva, Switzerland. http://www.who.int/whosis/ whostat/ EN_WHS08_Full.pdf

[2] The Atlas of heart disease and stroke, WHO 2004. http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf (Mackay J, Mensah G: The Atlas of Heart Disease and Stroke. Geneva, Switzerland, World Health Organization, 2004)

[3] RogerVL, GoAS, Lloyd-JonesDM, et al. . Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation, 2011, 123(4): e18-e209 PMID: 21160056 PMCID: 4418670

[4] SousaRM, FerriCP, AcostaD, et al. . Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet, 2009, 374(9704): 1821-1830 PMID: 19944863 PMCID: 2854331

[5] FeiginVL, LawesCM, BennettDA, et al. . Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol, 2003, 2(1): 43-53 PMID: 12849300

[6] YueJ, XiaoY, YanZ. Analysis of influence on the hospitalization expenditure of medical insurant patients with stroke. Mod Prev Med, 2008, 35: 71-73

[7] SecadesJJ, FronteraG. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol, 1995, 17: 1-54 PMID: 8709678

[8] TazakiY, SakaiF, OtomoE, et al. . Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke, 1988, 19(2): 211-216 PMID: 3278412

[9] SobrinoT, Rodriguez-GonzalezR, BlancoM, et al. . CDP-choline treatment increases circulating endothelial progenitor cells in acute ischemic stroke. Neurol Res, 2011, 33(6): 572-577 PMID: 21708065

[10] WarachS, PettigrewLC, DasheJF, et al. . Effect of citicoline on ischemic lesions as measured by diffusionweighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol, 2000, 48(5): 713-722 PMID: 11079534

[11] ChoHJ, KimYJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol, 2009, 31(3): 171-176 PMID: 19536360

[12] DavalosA, CastilloJ, Alvarez-SabinJ, et al. . Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke, 2002, 33(12): 2850-2857 PMID: 12468781

[13] DavalosA, Alvarez-SabinJ, CastilloJ, et al. . Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet, 2012, 380(9839): 349-357 PMID: 22691567

[14] Chinese Association of Neurosurgery, Chinese Society of Neurosciences.. Diagnostic key points of cerebrovascular diseases. Chin J Neurol, 1996, 6: 60-61

[15] WHO Special Report.. Stroke: recommendations on stroke prevention, diagnosis and therapy. Stroke, 1989, 20(10): 1407-1431

[16] HigginsJPT, DeeksJ editors. HigginsJPT, GreenS. Chapter 7: Selecting studies and collecting data. Cochrane handbook for systematic reviews of interventions (version 5.1.0), 2011, Chichester, John Wiley & Sons, Ltd, 1-28

[17] HigginsJPT, SterneJ editors. HigginsJPT, GreenS. Chapter 8: Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions (version 5.1.0), 2011, Chichester, John Wiley & Sons, Ltd, 1-53

[18] ClarkWM, WarachSJ, PettigrewLC, et al. . A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology, 1997, 49(3): 671-678

[19] ClarkWM, WilliamsBJ, SelzerKA, et al. . A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke, 1999, 30(12): 2592-2597 PMID: 10582983

[20] ClarkWM, WechslerLR, SabounjianLA, et al. . A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology, 2001, 57(9): 1595-602 PMID: 11706098

[21] SecadesJJ, Alvarez-SabinJ, RubioF, et al. . Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis, 2006, 21(5): 380-385 PMID: 16490951

[22] MittaM, GoelD, BansalKK, et al. . Edaravone-citicoline comparative study in acute ischemic stroke (ECCS-AIS). J Assoc Physicians India, 2012, 60: 36-38 PMID: 23767201

[23] LinWX. The therapeutic effect of edaravone for acute cerebral infarction. Chin J Integ Med Cardio-/Cerebrovasc Dis (Chinese), 2007, 5(3): 205-207

[24] TazakiY, SakaiF, OtomoE, et al. . Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke, 1988, 19(2): 211-216 PMID: 3278412

[25] SecadesJJ, LorenzoJL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol, 2006, 28: 1-56 PMID: 17171187

[26] IranmaneshF, VakilianA. Efficiency of citicoline in increasing muscular strength of patients with nontraumatic cerebral hemorrhage: a double-blind randomized clinical trial. J Stroke Cerebrovasc Dis, 2008, 17(3): 153-155 PMID: 18436157